Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Ejection fraction, Magnetic resonance imaging heart, Myocarditis, SARS-CoV-2 test, Troponin I
Clinical narrative: Cardiac Magnetic Resonance Imaging Demonstrating Acute Myocarditis; This literature-non-study case was reported in a literature article and describes the occurrence of MYOCARDITIS (Cardiac Magnetic Resonance Imaging Demonstrating Acute Myocarditis) in a 31-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.      The patient's past medical history included COVID-19 (She had a laboratory confirmed COVID-19 infection 7 months before) in November 2020.    In March 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In April 2021, the patient experienced MYOCARDITIS (Cardiac Magnetic Resonance Imaging Demonstrating Acute Myocarditis) (seriousness criterion medically significant). At the time of the report, MYOCARDITIS (Cardiac Magnetic Resonance Imaging Demonstrating Acute Myocarditis) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In April 2021, Ejection fraction: 57 percent (normal) normal. In April 2021, Magnetic resonance imaging heart: normal (normal) Normal systolic function with no regional wall motion abnormalities, pericardial effusion, thickening, or enhancement, acute myocarditis (abnormal) On T2 mapping, there were skip areas of epicardial edema involving the basal inferior, basal, mid, and apical lateral segments (59 ms-66 ms, normal <55 ms) and nonischemic myocardial injury on native T1 mapping (1,117 ms-1,137 ms, normal 950 ms-1,050 ms), acute myocarditis (abnormal) Epicardial fibrosis and acute myocarditis (abnormal) Interstitial expansion (40%-44%, normal <28%). In April 2021, SARS-CoV-2 test: negative (Negative) When the patient was presented to the emergency department. In April 2021, Troponin I: 7.961 (High) (normal <0.034 ng/mL).     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered MYOCARDITIS (Cardiac Magnetic Resonance Imaging Demonstrating Acute Myocarditis) to be possibly related.    Concomitant medications were not provided. Treatment information was not reported. The ischemic evaluation of the patient was negative at the time of emergency visit. The patient developed chest pressure 25 days after her first dose of the Moderna COVID-19 vaccine.  Company Comment: This is a literature report of a 31 years old woman with no previous cardiac history, who developed myocarditis 25 days after receiving first dose of the product. Based on the current available information and temporal association between the use of the product, and the start date of the events, a causal relationship cannot be excluded.; Sender's Comments: This is a literature report of a 31 years old woman with no previous cardiac history, who developed myocarditis 25 days after receiving first dose of the product. Based on the current available information and temporal association between the use of the product, and the start date of the events, a causal relationship cannot be excluded.